Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.32Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 35.00%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance driven by significant revenue growth, successful product launches, and expanded Medicaid coverage. However, challenges such as Q1 revenue fluctuations, Medicare Part D negotiations, and minimal contribution from the Kowa partnership were noted. The sentiment is balanced with optimism for future growth.Company Guidance
During the Arcutis Biotherapeutics 2024 Fourth Quarter and Full Year Financial Results Conference Call, the company outlined several key performance metrics and strategic goals for the upcoming year. The company reported $71 million in quarterly revenues, with $69 million derived from the ZORYVE franchise, including a $4 million nonrecurring adjustment. For the full year, revenues totaled $197 million, marking a significant 471% growth year-over-year in ZORYVE product sales. Looking forward to 2025, Arcutis plans to expand ZORYVE's indications, particularly with the anticipated PDUFA for scalp and body psoriasis slated for May 22, 2025. The company also emphasized the shift from topical steroids to non-steroidal options and aims to penetrate the government payer segment, with Medicaid coverage now reaching approximately half of the beneficiaries. Arcutis is focusing on leveraging its commercial partnership with Kowa to expand prescriber base beyond dermatology and noted a strong execution in securing insurance coverage, with gross-to-net ratios expected to remain steady in the 50s throughout 2025. The company projects continued revenue growth and aims to achieve cash break-even by 2026.Strong Revenue Growth
Arcutis reported $71 million in Q4 revenue with $69 million from the ZORYVE franchise, resulting in 471% year-over-year growth in ZORYVE product sales, reaching $167 million annually.
Expansion of ZORYVE Indications
ZORYVE foam was launched for seborrheic dermatitis and ZORYVE cream for atopic dermatitis. Upcoming PDUFA date in May 2025 for scalp and body psoriasis further broadens potential patient base.
Strong Prescription Volume Growth
ZORYVE prescription volume reached a new high with 16,000 weekly scripts in Q4, reflecting a 44% increase from the previous quarter and 334% growth year-over-year.
Success in Medicaid Coverage
Arcutis secured Medicaid coverage in states representing approximately 1 in 2 Medicaid beneficiaries, enhancing access to ZORYVE.
Notable Partnership
Arcutis partnered with Odell Beckham Jr. to increase awareness of seborrheic dermatitis and ZORYVE foam, generating over 1.5 billion media impressions within the first week.
---
ARQT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARQT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $12.20 | $13.22 | +8.36% |
| Nov 06, 2024 | $9.66 | $10.40 | +7.66% |
| Aug 14, 2024 | $9.58 | $8.50 | -11.27% |
| May 14, 2024 | $8.13 | $9.24 | +13.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcutis Biotherapeutics (ARQT) report earnings?
Arcutis Biotherapeutics (ARQT) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Arcutis Biotherapeutics (ARQT) earnings time?
Arcutis Biotherapeutics (ARQT) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARQT EPS forecast?
ARQT EPS forecast for the fiscal quarter 2025 (Q1) is -0.21.
---